Yhn ScienceBiology first seen 2 d ago, last 13 min ago, peak #4
Novo Nordisk and Eli Lilly report GLP-1 signs of slowed biological aging
Original: Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD
Drugmakers Novo Nordisk and Eli Lilly presented findings at the Aging Research and Drug Discovery meeting suggesting their GLP-1 drugs, already used for diabetes and obesity, may slow biological aging. The reports point to markers indicating slower aging processes in patients, fueling debate over whether these medicines could extend beyond weight loss into longevity treatment, and drawing wide attention from the research community and investors.
Why now: The possibility that widely used obesity drugs could also slow aging has major implications for medicine and the pharmaceutical market.
Novo NordiskEli LillyGLP-1 drugsARDD
Rank over time, top of the chart is #1. 15 snapshots from 11 h ago to 13 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2933411